Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. by Licata, A. et al.
IM - ORIGINAL
Serology in adults with celiac disease: limited accuracy in patients
with mild histological lesions
Anna Licata • Maria Cappello • Andrea Arini •
Ada M. Florena • Claudia Randazzo • Giuseppe Butera •
Piero L. Almasio • Antonio Craxı`
Received: 8 November 2010 / Accepted: 18 March 2011 / Published online: 6 April 2011
 SIMI 2011
Abstract Celiac disease (CD) is a gluten-triggered
enteropathy, presenting with insidious clinical patterns. It
can occasionally be diagnosed in asymptomatic subjects.
Our aim was to define the relationship among symptoms at
diagnosis, serological markers [tissue transglutaminase
antibodies (tTGA), anti-endomysium antibodies (EMA)
anti-actin antibodies (AAA)] and degree of mucosal dam-
age. A total of 68 consecutive adult patients with CD were
enrolled. Intestinal biopsies were scored according to the
Marsh classification modified by Oberhuber: I–II minimal
lesions or absent villous atrophy; IIIA partial villous atro-
phy; IIIB–C total villous atrophy (TVA). HLA-typing was
done for all patients. No association between clinical pre-
sentation and severity of mucosal damage was found.
Presence of EMA or tTGA was significantly associated
with more severe mucosal damage (P \ 0.001). Of 12
patients, 11 with AAA were also positive for TVA. The
severity of mucosal damage is the main factor governing
the detectability of serological markers of CD. The sensi-
tivity of serological testing is questionable in patients with
minimal lesions.
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Introduction
The prevalence of celiac disease (CD) in the general pop-
ulation varies widely around the world [1]. In Italy, about 1
in every 200 persons is estimated to have overt or latent CD
[2]. CD may cause non-specific symptoms, and is often
silent when found at screening of at-risk subjects. When
symptomatic, its features may mimic those of other dis-
eases, making the diagnosis challenging. Peculiar histo-
pathologic changes of the small bowel mucosa are
considered the gold standard of diagnosis [3], but random
biopsies are not always diagnostic because of the variable
expression and patchiness of lesions. The heterogeneity of
the degree and the extension of mucosal damage are at
least partially correlated with the clinical expression of CD
[4]. The gluten-triggered inflammatory response leads to
activation of the humoral pathway and production of
autoantibodies [5, 6], such as those against tissue trans-
glutaminase (tTGA) and endomysium (EMA), commonly
used to screen patients for small bowel biopsy and to assess
adherence to a gluten-free diet (GFD) [7, 8].
IgA tTGA and IgA EMA are considered the most sen-
sitive and specific serologic tests for CD. In children, they
are reported to have a sensitivity and specificity of above
95% [9, 10]. It is a well-established fact that increased
EMA and tTGA correlate with abnormal small bowel
histopathology [11]. Fewer data correlating serologic levels
with degree of villous atrophy are available. Clemente
et al. [12] found IgA antibodies against actin filaments
(AAA) in 60% of children and 90% of adults with severe or
moderate villous atrophy caused by CD. In their study, IgA
AAA were strongly correlated with more severe degrees of
intestinal villous atrophy.
The aims of this study were to characterize, in a pro-
spective cohort of Italian adult patients with a diagnosis of
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CD, the serological markers and to correlate them with the




A total of 68 adults consecutively seen as out- or inpatients
at our unit between January 2004 and December 2008, and
who received a final de novo diagnosis of CD, were
enrolled. All subjects were 18 years or older, had no pre-
vious diagnosis of CD and were on a normal diet with no
restrictions. Patients had been referred because of gastro-
intestinal symptoms (abdominal pain, diarrhea), systemic
signs (iron-deficiency anemia, cryptogenic chronic liver
damage, a family history of CD—any first-degree relative
with CD) or a recent diagnosis of type I diabetes or other
autoimmune disease. Patients were stratified into sub-
groups according to their clinical presentation of CD as
follows: classic presentation of CD (C-CD) with gastroin-
testinal symptoms; atypical presentation (A-CD) with iron-
deficiency anemia or high levels of aminotransferases;
silent disease (S-CD), detected on screening because of a
family history of CD. The final diagnosis of CD was based
on the National Institutes of Health Consensus Criteria
[13].
Histology
All patients underwent upper gastrointestinal endoscopy,
with small bowel biopsies. At least three specimens were
taken from the distal duodenum and oriented before fixa-
tion. Histological analyses of the biopsies were carried out
by an expert pathologist (A.F.) and scored according to the
Marsh classification [14] as follows: increase in intraepi-
thelial lymphocytes (IEL, grade I), increase in IEL with
crypt hyperplasia (grade II), mild villous flattening (grade
IIIA), marked villous flattening (grade IIIB) and total vil-
lous flattening (grade IIIC). The severity of intestinal
mucosa damage was graded according to the scale pro-
posed by Oberhuber et al. [15] as follows: partial villous
atrophy (PVA) for Marsh IIIA, subtotal villous atrophy
(STVA) for Marsh IIIB and total villous atrophy (TVA) for
Marsh IIIC. In this study, STVA and TVA were combined
as a severe form of villous damage (TVA).
Patients with Marsh III lesions and negative serology
were considered as having CD only if there was a clinical
and histological response to a GFD and no alternative
diagnosis to account for the histological abnormalities.
Marsh I–II lesions were considered nonspecific, but pos-
sibly consistent with CD, if serology was positive or the
patient responded to a GFD with improvement of the
mucosal architecture.
Serology
Venous blood samples were collected at the time of
endoscopy and tested for IgA EMA, IgA tTGA and IgA
AAA. Total serum IgA was measured to exclude selective
IgA deficiency. Serum IgA EMA was tested by indirect
immunofluorescence (IF) on a monkey esophagus substrate
(EUROIMMUN, Labordiagnostika, Lu¨beck, Germany).
Serum IgA tTGA was tested by ELISA, using recombinant
tissue transglutaminase as antigen (EUROIMMUN, La-
bordiagnostika, Lu¨beck, Germany). IgA AAA was tested
by IF on rat intestinal epithelial cells (EUROSPITAL,
Trieste, Italy).
HLA testing
Complete HLA-typing for DR and DQ alleles was per-
formed on genomic DNA extracted from peripheral blood
by polymerase chain reaction, with sequence-specific
primers at low and high resolution. Allele, genotype and
haplotype frequencies were studied. Three phenotype
groups were considered: HLA-DQ2 (homozygous or het-
erozygous for DQ2 and without DQ8), HLA-DQ2/-DQ8
and HLA-DQ8 (homozygous or heterozygous for DQ8 and
without DQ2).
Statistics
Continuous variables were summarized as mean ± stan-
dard deviation (SD) or median and range, and categorical
variables as frequency and percentage. Comparison of
continuous and categorical variables was made with the
Student’s t test, for normally distributed variables, the
Mann–Whitney U test, for not-normally distributed vari-
ables, and the v2 test. Data were analyzed with the Statis-
tical Package for Social Science (SPSS) version 13.0 for
Windows. Differences were reported as statistically sig-
nificant if the P value was \0.05.
Results
Demographic, clinical, laboratory and histological features
of the patients are shown in Table 1. The majority of
patients were women (77.9%) and the mean age at diag-
nosis was 40 years (range 18–80). Thirty-three patients
(48.5%) had a classic presentation of CD (C-CD) with
gastrointestinal symptoms (diarrhea, abdominal pain). Ten
of them also had anemia, seven abnormal liver tests, and
five a first-degree relative with CD. A total of 26 patients
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(38.2%) had an atypical presentation (A-CD), with iron-
deficiency anemia and/or high levels of aminotransferases.
Nine patients (13.3%) had a silent disease (S-CD), detected
upon screening because of a family history of CD. tTGA/
EMA were positive in 49 (72.1%) CD patients, and AAA
were present in 12 (17.6%). As much as 39 patients
(57.4%) carried HLA-DQ2, 22 (32.3%) HLA-DQ8 and 7
(10.3%) HLA-DQ2/DQ8 (Table 1).
No association was found between clinical presentation
and severity of mucosal damage (Table 2). tTGA/EMA
and IgA AAA showed no correlation with the clinical
presentation. The only variable statistically associated with
the clinical pattern was the ferritin value (P = 0.008).
When analyzed for the severity of intestinal mucosa dam-
age, tTGA/EMA were positive in 4/5 (80.0%) patients with
TVA (histopathology IIIC), in 29/33 (87.9%) patients with
STVA (histopathology IIIB) and in 13/18 (72.2%) patients
with PVA (histopathology IIIA). Three of 12 patients
(25.0%) with minimal histological lesions (histopathology
I–II) were tTGA/EMA positive. Among the ten patients
with villous atrophy and negative serology, the diagnosis
was made by integrating the histopatholic evaluation,
clinical pattern and the presence of HLA-DQ2/DQ8. Seven
Marsh I–II patients were diagnosed as suffering from CD
on the basis of response to a GFD, and two patients had
latent CD on the basis of family history.
tTGA/EMA positivity was much less frequent in
patients with minimal lesions (Marsh I–II) as compared to
PVA and TVA (25.0 vs. 72.2 vs. 86.8%, respectively;
P \ 0.001) (Table 3). IgA AAA were positive in 2/5
(40.0%) patients with TVA (histopathology IIIC), 9/33
(27.3%) patients with STVA (histopathology IIIB), 1/18
(5.5%) patients with PVA (histopathology IIIA) and in
none of the 12 patients with minimal histological lesions
(histopathology I–II). The association of positivity for
tTGA/EMA and AAA did not increase the sensitivity for
diagnosis of PVA and TVA.
Discussion
The gold standard for establishing a diagnosis of CD is the
presence of gluten-dependent intestinal histological lesions
[16]. Major problems are usually related to patchy lesions
or artifactual damage caused by the difficulty in handling
or correctly orienting biopsy tissues [3]. For these reasons,
serological assays are the primary screening for deciding to
perform an intestinal sampling [17]. Nonetheless, adult
patients with mild or moderate mucosal changes are more
frequently seronegative for tTGA/EMA than children [18].
In both children and adults, high titers of EMA and tTGA
are found in patients with severely abnormal small bowel
mucosa [10, 17–22]. Data on lesser degrees of villous
atrophy in relation to EMA and tTGA are discordant,
making the role of serology unclear when duodenal biopsy
is not reliable for diagnosing CD with a certain degree of
confidence. Establishing a correlation between positive
serology and small bowel histopathology has considerable
clinical utility. We observe a significant correlation
between Marsh III histopathology and positive tTGA/EMA
serology, as reported by other studies [23]. Presence of
EMA or tTGA in our study was significantly associated
with more severe villous atrophy. Sensitivity of serological
testing is questionable among patients presenting with
PVA, thus reducing its effectiveness in clinical practice
[12, 18, 19, 22]. Rostami et al. [23] show that EMA has a
lower sensitivity in CD patients with milder intestinal
damage. Tursi et al. [18] observe, in 119 adults, that the
prevalence of tTGA seropositivity and the mean tTGA titer
are higher in CD patients with more severe inflammation at
biopsy. Hence, a finding of tTGA/EMA seropositivity at a
high titer may predict severe villous atrophy in patients
with a suspected diagnosis of CD, though negative serol-
ogy does not exclude a diagnosis of CD.
In our series, only three patients with Marsh I–II were
tTGA/EMA positive and had gastrointestinal complaints
Table 1 Main clinical, serological and histological data at diagnosis




Age (years, mean ± SD) 40.0 ± 16.0
Hemoglobin (g/dL) (mean ± SD) 12.3 ± 1.9
Ferritin (ng/mL) (median, range) 17.5 (3–1,532)
ALT (UI/l) (median, range) 23 (9–183)




Autoimmune disease 13 (19.1%)
Duodenal histology
Minimal lesions 12 (17.6%)
PVA 18 (26.5%)
TVA 38 (55.9%)
IgA tTGA/EMA positive 49 (72.1%)





C-CD classic celiac disease, A-CD atypical celiac disease, S-CD silent
celiac disease, PVA partial villous atrophy, TVA total villous atrophy,
tTGA tissue transglutaminase antibodies, EMA anti-endomysium
antibodies, AAA anti-actin antibodies
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suggestive of early CD. According to a recent update, these
could also be classified as potential CD [24]. It must be
stressed, however, that the small bowel lesions of CD may
be patchy [25], and that we had no way of measuring the
extent of the lesions throughout the small bowel in our
patients. In the case of positive tTGA/EMA with Marsh II
or lesser lesions, higher grade pathology may have been
missed by sampling error. Serology markers were positive
not only in almost all CD patients with subtotal and total
villous atrophy, but also in 72.2% of CD patients with PVA
and in 3 out of 12 patients with minimal lesions.
Despite serologic, histopathologic and clinical data, the
diagnosis may remain unclear in some patients. As
expected in our cohort, there were negative serologies in
17.9% of patients with Marsh III lesions. Intermediate
Marsh grades and PVA have been associated with negative
serology [16]. Dickey et al. [25] show that one out of five
EMA-negative CD patients have Marsh IIIA lesions. Vil-
lous atrophy in the context of negative serology may result
from non-gluten-sensitive enteropathy disease [26]. False-
positive biopsies may also result from overinterpretation of
specimens or poor specimen orientation. Of 19 patients, 9
with negative serology had minimal lesions; these patients,
despite HLA compatibility and response to GFD, would
not be celiac according to Biagi et al. [27], but would be
considered gluten-sensitive patients, according toVerdu
et al. [28].
In the past few years, IgA AAA have been found in CD
patients, and a close correlation has emerged between the
presence of AAA and mucosal damage [29]. Our data
indicate that 28.9% of patients with TVA are AAA sero-
positive. Although AAA cannot replace EMA and tTGA in
the diagnostic algorithm of CD, testing for the presence of
both tTGA/EMA and AAA in subjects at high risk of CD
(such as first-degree relatives) and with CD-related symp-
toms might be a useful tool in the follow-up of patients
with severe disease to monitor the response to GFD [30].
As much as 90% of CD patients carry the HLA-DQ2
molecule, while approximately 5% express HLA-DQ8.
Although genetic and environmental factors involved in the
development of CD are already understood, it still unclear
what it is that determines whether patients develop the
classic or atypical form of the disease. Patients who are
homozygous for HLA-DQ2 have a higher risk of devel-
oping CD than those who are heterozygous The association
between HLA-DQ2 homozygosity and more severe villous
atrophy is observed in a Finnish cohort of adult CD
patients, while in an Italian cohort there is no correlation
Table 2 Epidemiological, clinical and serological data of patients with celiac disease according to clinical presentation
C-CD (n = 33) A-CD (n = 26) S-CD (n = 9) P
Gender
Male 6 (18.2%) 6 (23.1%) 3 (33.3%) 0.6
Female 27 (81.8%) 20 (76.9%) 6 (66.7%)
Age (years, mean ± SD) 41.9 ± 19.2 38.5 ± 13.6 40.4 ± 15.1 0.7
Hemoglobin (g/dL) (mean ± SD) 12.1 ± 2.1 12.0 ± 1.9 13.7 ± 0.9 0.06
Ferritin (ng/mL) (median, range) 22 (3–1.256) 9.5 (4–1.532) 68 (15–131) 0.008
ALT (UI/l) (median, range) 23 (9–90) 27.5 (9–183) 18 (13–35) 0.2
Autoimmune disease 8 (24.2%) 5 (19.2%) 0 0.3
Duodenal histology
Minimal lesions 5 (15.2%) 4 (15.4%) 3 (33.3%) 0.5
PVA 8 (24.2%) 9 (34.6%) 1 (11.1%)
TVA 20 (60.6%) 13 (50.0%) 5 (55.6%)
IgA tTGA/EMA positive 23 (69.7%) 20 (76.9%) 6 (66.7%) 0.8
IgA AAA positive 7 (21.2%) 5 (19.2%) 0 0.3
Any combination of tTGA/EMA/AAA 24 (72.7%) 21 (80.8%) 6 (66.7%) 0.6
C-CD classic celiac disease, A-CD atypical celiac disease, S-CD silent celiac disease, PVA partial villous atrophy, TVA total villous atrophy,
tTGA tissue transglutaminase antibodies, EMA anti-endomysium antibodies, AAA anti-actin antibodies
Table 3 Frequency of Ttga/EMA and AAA positivity according to





(n = 12) (n = 18) (n = 38)
tTGA/EMA 3 (25.0%) 13 (72.2%) 33 (86.8%) \0.001




3 (25.0%) 14 (77.7%) 33 (86.8%) \0.001
PVA partial villous atrophy, TVA total villous atrophy, tTGA tissue
transglutaminase antibodies, EMA anti-endomysium antibodies, AAA
anti-actin antibodies
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with clinical presentation and mucosal damage [31, 32].
The prevalence of -DQ2 and -DQ8 heterodimers (57.4 and
32.3%) in our study confirms the evidence of a strong
genetic predisposition to CD. We find an influence of
HLA-DQ2/-DQ8 status on the degree of villous atrophy, as
previously suggested [33]. In our cohort there is a tendency
toward a higher predominance of the HLA-DQ2/-DQ8
genotype in patients with TVA (data not shown).
Though it is conceivable that more severe intestinal
damage is correlated with a symptomatic presentation, we
are unable to find a link between the degree of villous
atrophy and the disease, as shown in another study [33].
However, it must be stressed that CD mucosal lesions
might be patchy [4], and that we had no way of measuring
the extent of the lesions throughout the small bowel in our
patients. The area of involved mucosa may be another
major determinant of the clinical expression of CD and
should be assessed by video capsule endoscopy studies
[34].
In conclusion, our data show that IgA tTGA and EMA
predict villous atrophy on biopsy. The sensitivity of sero-
logical testing is questionable among patients with minimal
lesions. We believe that these results call for further vali-
dation in a larger series. Until then, duodenal biopsy
remains the gold standard for confirmation of the diagnosis.
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